8-K: SANUWAVE Health Announces Record Quarterly and Full Year Revenues for 2024, Provides Optimistic 2025 Guidance

SANUWAVE Health reports record Q4 and full-year 2024 revenues, driven by strong UltraMist system sales and consumables, and issues promising revenue guidance for 2025.

Summary

• SANUWAVE Health, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2024.
• Q4 2024 revenues reached a record $10.3 million, a 47% increase compared to Q4 2023.
• Full year 2024 revenues also hit a record $32.6 million, up 60% from the previous year.
• The company's Q4 2024 gross margin was 77.9%, compared to 69.1% in Q4 2023.
• Full year 2024 gross margin was 75.2%, an increase from 70.4% in 2023.
• GAAP Operating Income was $2.5 million for Q4 2024 and $5.4 million for the full year.
• The company is providing revenue growth guidance of 45-55% for Q1 2025 compared to Q1 2024.
• Full year 2025 revenue guidance is set at $48-50 million, representing a 47-53% increase versus 2024.
• Net loss for the fourth quarter of 2024 was $12.7 million, driven predominantly by the change in the fair value of derivative liabilities, valuation adjustments resulting from the share and warrant exchange, and the extinguishment of debt.
• Net loss for 2024 was $31.4 million, driven predominantly by the change in the fair value of derivative liabilities.
• Adjusted EBITDA for Q4 2024 was $3.7 million, a $3.0 million improvement from Q4 2023.
• Adjusted EBITDA for the full year 2024 was $7.2 million, compared to a negative $1.2 million in 2023, an $8.4 million improvement.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenues and strong growth guidance, but the net losses due to derivative liabilities temper the overall sentiment.

Positives

• Record quarterly and full-year revenues indicate strong growth and market acceptance of SANUWAVE's products.
• Improved gross margins demonstrate increased efficiency and profitability.
• Positive Adjusted EBITDA for both Q4 and full year 2024 signals a turnaround in financial performance.
• Strong revenue guidance for 2025 suggests continued growth momentum.
• Increased sales of UltraMist systems and consumables highlight the success of the company's primary revenue driver.
• The company simplified its capital structure in October 2024 and uplisted to the Nasdaq Global Market in March 2025.

Negatives

• Net losses for both Q4 2024 and full year 2024, primarily due to changes in the fair value of derivative liabilities, raise concerns about financial stability.
• The company's balance sheet shows a stockholders deficit of $12.7 million as of December 31, 2024.

Risks

• Fluctuations in the fair value of derivative liabilities can significantly impact net income.
• Competition in the wound care market could affect future growth.
• Regulatory oversight and the company's ability to manage capital resources are key risks.
• The company's reliance on UltraMist systems and consumables for the majority of its revenue makes it vulnerable to changes in demand for these products.

Future Outlook

The Company forecasts Q1 2025 revenue of $8.4 to $9.0 million (45-55% increase from Q1 2024) and initiates full year 2025 revenue guidance of $48-50 million (47-53% increase as compared to full year 2024 revenue).

Management Comments

• The fourth quarter once more setting an all-time record for quarterly revenue was a fitting end to a transformational year at Sanuwave, said Morgan Frank, CEO.
• Obviously, we're very pleased with these results both for the quarter, and for the year as a whole.
• We're especially excited about our gains in gross margin and adjusted EBITDA, allowing us to continue the trend of having positive cash flows from operations even after cash interest expense, that we began in Q3 2024.
• This feels like turning a corner.
• Having greatly simplified our capital structure in October 2024 and now having uplisted to the Nasdaq Global Market in March of this year, 2025 shows every sign of being a breakout year for Sanuwave.

Industry Context

The wound care market is experiencing growth due to an aging population and increasing prevalence of chronic diseases like diabetes. SANUWAVE's focus on regenerative medicine and non-invasive technologies positions it well to capitalize on these trends. Competitors in this space include companies offering advanced wound dressings, biologics, and negative pressure wound therapy.

Comparison to Industry Standards

• Comparing SANUWAVE's revenue growth of 60% in 2024 to companies like Smith & Nephew (SNN), which reported underlying revenue growth of 7.9% in 2023, highlights SANUWAVE's rapid expansion.
• Organogenesis Holdings Inc. (ORGO) reported net revenue increase of 11.9% for the year ended December 31, 2023, which is significantly lower than Sanuwave's 60% revenue growth.
• SANUWAVE's gross margin of 75.2% is competitive with industry leaders like Integra LifeSciences (IART), which reported an adjusted gross margin of 68.4% for the full year 2023.
• However, it's important to note that SANUWAVE's net losses contrast with the profitability of some larger players in the wound care market.

Stakeholder Impact

• Shareholders will likely react positively to the record revenues and strong growth guidance.
• Employees may benefit from the company's improved financial performance and growth prospects.
• Customers can expect continued innovation and availability of SANUWAVE's wound care products.
• Suppliers may see increased demand for their products and services as SANUWAVE expands its operations.
• Creditors may view the company as a lower credit risk due to its improved financial performance.

Next Steps

• The company will continue to ramp up its sales force and sales strategy.
• SANUWAVE will share further progress in future quarters.

Key Dates

Keywords

SANUWAVE, UltraMist, revenue, wound care, financial results, EBITDA, gross margin, guidance